GlassScriptPhysician profile
Thomas W Price
NPI 1285610055
$3,511.88
in general payments reported to CMS, 2019-2025
33 companies · $95.19 in 2025
The $95.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $156 · 2021: $645 · 2022: $579 · 2023: $1,200 · 2024: $580 · 2025: $95.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856 · Consulting Fee: $18.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.74 |
| Consulting Fee | $18.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $485.53 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Takeda Pharmaceuticals U.S.A., INC. | $388.60 | 2020-2024 | Hyqvia |
| Amgen INC. | $362.51 | 2019-2023 | Tavneos, Enbrel, Amjevita |
| Janssen Biotech, INC. | $325.42 | 2019-2023 | Symtuza, Stelara, Simponi |
| Gilead Sciences, INC. | $285.76 | 2021-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $259.19 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Melinta Therapeutics, LLC | $238.40 | 2019-2024 | Vabomere, Orbactiv, Kimyrsa |
| Viiv Healthcare Company | $145.75 | 2021-2023 | Rukobia |
| Aurinia Pharma U.S., INC. | $111.44 | 2021-2023 | Lupkynis |
| Smith+Nephew, INC. | $94.72 | 2020-2024 | Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $82.96 | 2023-2024 | Nuzyra |
| Organogenesis INC. | $79.61 | 2023-2025 | Puraply, Simplimax |
| Csl Behring | $68.17 | 2021-2023 | Hizentra |
| Pfizer INC. | $59.88 | 2023-2024 | |
| Horizon Therapeutics Plc | $58.10 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $55.95 | 2023-2024 | Fetroja |
| Grifols USA, LLC | $46.82 | 2022-2024 | Xembify |
| Convatec INC. | $41.39 | 2023 | |
| Adma Biomanufacturing LLC | $38.49 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $30.28 | 2023 | |
| Genzyme Corporation | $29.69 | 2023 | |
| Shire North American Group INC | $26.57 | 2019 | |
| Octapharma USA, INC. | $22.75 | 2022 | |
| Solventum Corporation | $22.68 | 2025 | Promogran Prisma, 3m Cavilon, Activ.A.C. |
| Allergan, INC. | $21.65 | 2019 | |
| Lilly USA, LLC | $20.03 | 2023 | Taltz |
| Abbvie INC. | $20.00 | 2022 | |
| Abbott Laboratories | $18.70 | 2022 | |
| Bioventus LLC | $16.97 | 2022 | |
| Seqirus USA INC | $14.66 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.82 | 2021 | |
| Mayne Pharma Commercial LLC | $13.42 | 2021 | |
| Kci USA, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.